Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma

J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e257-e258. doi: 10.1111/jdv.14371. Epub 2017 Jul 19.

Authors

E Degache¹, J Crochet¹, N Simon², M Tardieu¹, S Trabelsi¹, M Moncourier¹, I Templier¹, L Foroni³, A Lemoigne³, N Pinel⁴, H Gil⁴, L Bouillet², M T Leccia^{1

5}, J Charles^{1

5}

Affiliations

¹ Service de Dermatologie, CHU Grenoble Alpes, Grenoble, France.
² Service de Médecine Interne, CHU Grenoble Alpes, Grenoble, France.
³ Service de Pharmacie, CHU Grenoble Alpes, Grenoble, France.
⁴ Département d'anatomie et Cytologie Pathologiques, CHU Grenoble Alpes, Grenoble, France.
⁵ INSERM, U1209, Université Grenoble Alpes, Grenoble, France.

PMID: 28557105
DOI: 10.1111/jdv.14371

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Squamous Cell / therapy*
Facial Neoplasms / therapy*
Humans
Male
Neck
Skin Neoplasms / therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab